Blood glucose-lowering nuclear receptor agonists only partially normalize hepatic gene expression in db/db mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 316, Issue 2, 2006, Pages 797-804

  Loffler, Michael ^a,b   Bilban, Martin ^a   Reimers, Mark ^c   Waldhäusl, Werner ^a,b   Stulnig, Thomas M ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOCORTICOID; GROWTH HORMONE RECEPTOR; LIVER X RECEPTOR AGONIST; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; NUCLEAR RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIRINIXIC ACID; ROSI; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DNA MICROARRAY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; ENDOPLASMIC RETICULUM; GENE EXPRESSION REGULATION; GENE TARGETING; GLUCOSE HOMEOSTASIS; LIPID METABOLISM; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEPTOR INTRINSIC ACTIVITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; GENE EXPRESSION; GENE EXPRESSION PROFILING; HYPOGLYCEMIC AGENTS; LIPID METABOLISM; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MULTIGENE FAMILY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PPAR GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; THIAZOLIDINEDIONES;

EID: 31144445475     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.093831     Document Type: Article

References (40)

1. Anderson SP, Dunn C, Laughter A, Yoon L, Swanson C, Stulnig TM, Steffensen KR, Chandraratna RAS, Gustafsson JÅ, and Corton JC (2004) Overlapping transcriptional programs regulated by peroxisome proliferator-activated receptor alpha, retinoid X receptor and liver X receptor in the mouse liver. Mol Pharmacol 66:1440-1452.
2. Aoki K, Homma M, Hirano T, Oka K, Satoh S, Mukasa K, Ito S, and Sekihara H (2001) MRNA and enzyme activity of hepatic 11beta-hydroxysteroid dehydrogenase type 1 are elevated in C57BL/KsJ-db/db mice. Life Sci 69:2543-2549.
3. Bujalska IJ, Walker EA, Tomlinson JW, Hewison M, and Stewart PM (2002) 11Betahydroxysteroid dehydrogenase type 1 in differentiating omental human preadipocytes: from de-activation to generation of cortisol. Endocr Res 28:449-461.
4. Cao G, Liang Y, Broderick CL, Oldham BA, Beyer TP, Schmidt RJ, Zhang Y, Stayrook KR, Suen C, Otto KA, et al. (2003) Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis. J Biol Chem 278:1131-1136.
5. Chisholm JW, Hong J, Mills SA, and Lawn RM (2003) The LXR ligand T0901317 induces severe lipogenesis in the db/db diabetic mouse. J Lipid Res 44:2039-2048.
6. Dominici FP and Turyn D (2002) Growth hormone-induced alterations in the insulin-signaling system. Exp Biol Med (Maywood) 227:149-157.
7. Draper N, Walker EA, Bujalska IJ, Tomlinson JW, Chalder SM, Arlt W, Lavery GG, Bedendo O, Ray DW, Laing I, et al. (2003) Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nat Genet 34:434-439.
8. Edvardsson U, Alexandersson M, Brockenhuus von Lowenhielm H, Nystrom AC, Ljung B, Nilsson F, and Dahllof B (1999) A proteome analysis of livers from obese (ob/ob) mice treated with the peroxisome proliferator WY14,643. Electrophoresis 20:935-942.
9. Efanov AM, Sewing S, Bokvist K, and Gromada J (2004) Liver X receptor activation stimulates insulin secretion via modulation of glucose and lipid metabolism in pancreatic beta-cells. Diabetes 53:S75-78.
10. Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, et al. (2000) Peroxisome proliferator activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem 275:16638-16642.
11. Haemmerle G, Zimmermann R, Strauss JG, Kratky D, Riederer M, Knipping G, and Zechner R (2002) Hormone-sensitive lipase deficiency in mice changes the plasma lipid profile by affecting the tissue-specific expression pattern of lipoprotein lipase in adipose tissue and muscle. J Biol Chem 277:12946-12952.
12. Hori H, Sasaoka T, Ishihara H, Wada T, Murakami S, Ishiki M, and Kobayashi M (2002) Association of SH2-containing inositol phosphatase 2 with the insulin resistance of diabetic db/db mice. Diabetes 51:2387-2394.
13. Ide T, Shimano H, Yoshikawa T, Yahagi N, Amemiya-Kudo M, Matsuzaka T, Nakakuki M, Yatoh S, Iizuka Y, Tomita S, et al. (2003) Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism: II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling. Mol Endocrinol 17:1255-1267.
14. Iida K, Del Rincon JP, Kim DS, Itoh E, Nass R, Coschigano KT, Kopchick JJ, and Thorner MO (2004) Tissue-specific regulation of growth hormone (GH) receptor and insulin-like growth factor-I gene expression in the pituitary and liver of GH-deficient (lit/lit) mice and transgenic mice that overexpress bovine GH (bGH) or a bGH antagonist. Endocrinology 145:1564-1570.
15. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, and Speed TP (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31:e15.
16. Issemann I and Green S (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature (Lond) 347:645-650.
17. Laffitte BA, Chao LC, Li J, Walczak R, Hummasti S, Joseph SB, Castrillo A, Wilpitz DC, Mangelsdorf DJ, Collins JL, et al. (2003) Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci USA 100:5419-5424.
18. Lan H, Rabaglia ME, Stoehr JP, Nadler ST, Schueler KL, Zou F, Yandell BS, and Attie AD (2003) Gene expression profiles of nondiabetic and diabetic obese mice suggest a role of hepatic lipogenic capacity in diabetes susceptibility. Diabetes 52:688-700.
19. Lee AH, Iwakoshi NN, and Glimcher LH (2003) XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. Mol Cell Biol 23:7448-7459.
20. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, and Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12953-12956.
21. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, and Flier JS (2001) A transgenic model of visceral obesity and the metabolic syndrome. Science (Wash DC) 294:2166-2170.
22. Miyazaki M, Dobrzyn A, Man WC, Chu K, Sampath H, Kim HJ, and Ntambi JM (2004) Stearoyl-CoA desaturase 1 gene expression is necessary for fructosemediated induction of lipogenic gene expression by sterol regulatory element-binding protein-1c-dependent and -independent mechanisms. J Biol Chem 279: 25164-25171.
23. Nadler ST and Attie AD (2001) Please pass the chips: genomic insights into obesity and diabetes. J Nutr 131:2078-2081.
24. Ntambi JM, Miyazaki M, Stoehr JP, Lan H, Kendziorski CM, Yandell BS, Song Y, Cohen P, Friedman JM, and Attie AD (2002) Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc Natl Acad Sci USA 99:11482-11486.
25. Oakes ND, Kennedy CJ, Jenkins AB, Laybutt DR, Chisholm DJ, and Kraegen EW (1994) A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 43:1203-1210.
26. Özcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Gorgun C, Glimcher LH, and Hotamisligil GS (2004) Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science (Wash DC) 306:457-461.
27. Ramsay RR, Gandour RD, and van der Leij FR (2001) Molecular enzymology of carnitine transfer and transport. Biochim Biophys Acta 1546:21-43.
28. Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, Shan B, Brown MS, Goldstein JL, and Mangelsdorf DJ (2000) Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 14:2819-2830.
29. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, Schwendner S, Wang S, Thoolen M, Mangelsdorf DJ, et al. (2000) Role of LXRs in control of lipogenesis. Genes Dev 14:2831-2838.
30. Sekoguchi E, Sato N, Yasui A, Fukada S, Nimura Y, Aburatani H, Ikeda K, and Matsuura A (2003) A novel mitochondrial carnitine-acylcarnitine translocase induced by partial hepatectomy and fasting. J Biol Chem 278:38796-38802.
31. Seo JB, Moon HM, Kim WS, Lee YS, Jeong HW, Yoo EJ, Ham J, Kang H, Park MG, Steffensen KR, et al. (2004) Activated liver X receptors stimulate adipocyte differentiation through induction of peroxisome proliferator-activated receptor gamma expression. Mol Cell Biol 24:3430-3444.
32. Storey JD and Tibshirani R (2003) Statistical significance for genome wide studies. Proc Natl Acad Sci USA 100:9440-9445.
33. Stulnig TM, Oppermann U, Steffensen KR, Schuster GU, and Gustafsson JÅ (2002a) Liver X receptors downregulate 11β-hydroxysteroid dehydrogenase type 1 expression and activity. Diabetes 51:2426-2433.
34. Stulnig TM, Steffensen KR, Gao H, Reimers M, Dahlman-Wright K, Schuster GU, and Gustafsson JÅ (2002b) Novel roles of liver X receptors exposed by gene expression profiling in liver and adipose tissue. Mol Pharmacol 62:1299-1305.
35. Van Veldhoven PP and Mannaerts GP (1999) Role and organization of peroxisomal beta-oxidation. Adv Exp Med Biol 466:261-272.
36. Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, Edwards PA, and Tontonoz P (2000) Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci USA 97:12097-12102.
37. Way JM, Harrington WW, Brown KK, Gottschalk WK, Sundseth SS, Mansfield TA, Ramachandran RK, Willson TM, and Kliewer SA (2001) Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 142:1269-1277.
38. Willson TM, Brown PJ, Sternbach DD, and Henke BR (2000) The PPARs: from orphan receptors to drug discovery. J Med Chem 43:527-550.
39. Yakar S, Setser J, Zhao H, Stannard B, Haluzik M, Glatt V, Bouxsein ML, Kopchick JJ, and LeRoith D (2004) Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Investig 113:96-105.
40. Yoshida H, Matsui T, Yamamoto A, Okada T, and Mori K (2001) XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 107:881-891.